From the Journals

BP Targets Across CKM Stages

Investigators assess stage-specific outcomes, safety, and net benefit of intensive blood pressure control in cardiovascular-kidney-metabolic syndrome.

Share

Intensive blood pressure control to below 130/80 mmHg may lower major adverse cardiovascular events in patients with cardiovascular-kidney-metabolic syndrome (stages II to IV). This conclusion comes from a secondary analysis of a large-scale trial involving 33,736 participants aged 40 and above from rural China, with a median follow-up of over 3 years. Notably, the intervention showed the most significant reduction in stroke, while hypotension was more frequent in the intensive treatment group. The findings have limitations, reflecting the trial's rural context and potential confounding factors.

Original Source(s)

BP Targets Across CKM Stages

Investigators assess stage-specific outcomes, safety, and net benefit of intensive blood pressure control in cardiovascular-kidney-metabolic syndrome.

  • by Kathryn Wighton

  • February 19, 2026

  • 3 min

Related Content

Statin Side Effects Largely Unsupported by Trial Data

Most adverse effects listed on drug labels lack causal evidence, meta-analysis finds

Earlier Cardiovascular Risk in South Asians

Study finds earlier onset of diabetes and hypertension in US adults

  • February 17, 2026

  • 2 min
Despite Progress, Heart Disease Still Nation's Leading Killer

Recent statistics show some encouraging news in the fight against cardiovascular disease. Following a five-year upward trend that was likely influenced by the COVID-19 pandemic, the number of deaths from heart disease and stroke has declined.

  • by

  • February 4, 2026

  • 7 min